The ADVA X3 is a fully automated platform for manufacturing cell therapies that streamlines processes, reduces costs, and ensures the quality and availability of therapies for patients, according to an Adva spokesperson. By incorporating Opencell’s cost-effective, scalable, and continuous Softporation technology, Adva’s platform will offer an even more advanced and comprehensive solution, continued the spokesperson, who added that the partnership signifies a significant advancement in the manufacturing of cell and gene therapies, enhancing efficiency, scalability, and cost-effectiveness for superior biological outcomes.
“This partnership will enable us to provide a seamless, integrated solution that is not only robust and scalable but also exceptionally gentle on cells, ensuring superior outcomes for patients worldwide while leveraging the full potential of Adva’s technology,” said Behzad Mahdavi, PhD, executive chairman of Opencell.
“The addition of Opencell’s Softporation system to our ADVA X3® platform will allow us to meet the evolving needs of our customers with a solution that is both flexible and cutting-edge,” pointed out Ohad Karnieli, CEO of Adva.
The partnership is structured as a nonexclusive commercial agreement. Adva will offer Opencell’s Softporation technology as an optional feature within its platform, allowing customers to incorporate it into their manufacturing processes. Both companies retain ownership of their respective intellectual property, ensuring continued innovation and flexibility.
The collaboration will advance through a series of development and validation phases, leading to a commercial launch. Both companies will jointly focus on technology integration, marketing, customer education, and ongoing support to ensure the successful adoption of the integrated solution.
